Tag:

Novartis

Latest Headlines

Latest Headlines

Roche, Novartis face $1.6B in damages on Italy's Lucentis collusion ruling

Three months ago, antitrust authorities in Italy fined Novartis and Roche $251 million on charges they colluded to protect sales of their eye drug, Lucentis. Now, that country's Health Ministry is seeking further damages.

Top 10 best-selling vaccines of 2013

The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.

The EU's not impressed with Novartis' 'breakthrough' cardio drug, either

After an FDA rejection and an earlier negative opinion, Novartis' cardio treatment serelaxin has again failed to sway European regulators, and the drugmaker has resigned that its breakthrough-designated therapy will not hit any market this year.

Novartis, Boehringer vie for COPD market share with combo meds

Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.

Need a job? J&J, Novartis and Biogen Idec are pharma's favorite employers

With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.

Novartis hands Ophthotech a $1B deal for heavyweight wet AMD contender

Novartis has scooped up the ex-U.S. rights to Ophthotech's Fovista--its late-stage therapy for wet age-related macular degeneration that hopes to one day rival heavyweight franchises controlled by Roche and Regeneron--in a package deal potentially worth more than $1 billion.

FDA rejects Novartis' 'breakthrough' cardio drug serelaxin

The FDA rejected the heart drug serelaxin, the latest blow to a treatment Novartis hoped would be a cornerstone of a cardiovascular franchise.

HCL Tech adds Novartis to roster of Big Pharma clients

India-based HCL Technologies has shown a skill for winning Big Pharma contracts, like the $500 million deal it inked with Merck in 2010. HCL has now added Novartis to its list of clients, with the Swiss pharma signing up to outsource its infrastructure management to the IT services company.

Novartis settles Sun Pharma suit, winning 7-month reprieve from generic Gleevec

After nearly a year of fighting to protect the patent on its blockbuster leukemia drug Gleevec, Novartis has made peace with Indian drugmaker Sun Pharma, reaching a settlement that will keep Sun's generic version off the U.S. market until February 2016, Reuters reports. Novartis' U.S. patent expires in July 2015.

Novartis, Servier team up on tumor-killing drug development

France's Servier has struck up a deal with Novartis to develop oncology drugs that invade tumors and lead them to self-destruct.